Universität Wien

301908 VO Development of novel cancer immunotherapies (2023S)

from target identification through target validation to clinical trials

3.00 ECTS (2.00 SWS), SPL 30 - Biologie

Registration/Deregistration

Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).

Details

Language: English

Examination dates

Lecturers

Classes (iCal) - next class is marked with N

-digitale Lehre-
blocked., starts in april
more information follows

Monday 24.04. 14:00 - 16:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
Monday 08.05. 16:00 - 18:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
Monday 22.05. 15:30 - 17:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
Tuesday 30.05. 13:00 - 15:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
Tuesday 06.06. 14:00 - 16:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
Monday 19.06. 14:00 - 16:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
Monday 26.06. 09:00 - 17:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien

Information

Aims, contents and method of the course

The aim of the lecture is to transport the basic molecular, cellular and technological knowledge that is important for our understanding of current resistance mechanisms occurring in current immunotherapies. In Part II I will discuss state of the art methods which are currently employed to enhance our understanding of these mechanisms at play.

Assessment and permitted materials

Written exam, alternative: presentation

Minimum requirements and assessment criteria

Understanding of the basic mechanisms of resistance development and of newest technologies

Examination topics

Reading list


Association in the course directory

MMB IV-2,MMB W-2, MMEI II-3.2, MGE III-1, MMEI III, WZB, MMB IV.

Last modified: Tu 19.03.2024 16:06